|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's range||206.91 - 213.11|
|52-week range||173.45 - 248.87|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2023 - 14 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||238.92|
WASHINGTON (Reuters) -Illumina on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest cancer diagnostic test maker Grail over competition concerns in the U.S. market for cancer tests. San Diego-based Illumina is arguing that the FTC "violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal," according to the filing in the U.S. Fifth Circuit Court of Appeals.
Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On Friday it named Stephen MacMillan, CEO of diagnostics products company Hologic Inc, and Scott Ullem, CFO of heart valve systems maker Edwards Lifesciences Corp, as new directors. Wall Street analysts welcomed the move, with analysts at Evercore ISI writing: "Steve and Scott are well known and respected by Wall Street and should bring a ton of confidence into the (Illumina) story."
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Illumina Inc CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday. It gives deSouza legitimacy to carry on after Icahn mustered enough shareholder support to oust Illumina's board chair John Thompson and install one of his board nominees, Andrew Teno.
Insiders were net sellers of Illumina, Inc.'s ( NASDAQ:ILMN ) stock during the past year. That is, insiders sold more...
NEW YORK (Reuters) -Carl Icahn secured a seat on Thursday for one of his three nominees to the board of gene sequencing machine maker Illumina Inc, a partial victory for the activist investor who is struggling to burnish his credentials following a shortseller attack on his company. Illumina said Icahn nominee Andrew Teno won enough shareholder votes for election, confirming an earlier Reuters report. Illumina's market value of $30 billion made the fight this year's largest proxy contest to go to a shareholder vote.
(Bloomberg) -- Illumina Inc. shareholders voted to elect a board member nominated by activist shareholder Carl Icahn, a much-needed partial victory for the billionaire as his investment firm grapples with an attack by short-seller Hindenburg Research. Most Read from BloombergCathie Wood’s ARKK Dumped Nvidia Stock Before $560 Billion SurgeApple Plans to Turn Locked iPhones Into Smart Displays With iOS 17JPMorgan Tells 1,000 First Republic Employees They'll Lose Their JobsFirst Republic’s $35 Mill
Investing.com -- Stocks are mixed on Thursday as tech gets a boost from Nvidia's strong outlook while Dow stocks are weaker on a lack of resolution in the debt ceiling negotiations. Here are the market movers for May 25.
NEW YORK (Reuters) -Activist investor Carl Icahn is set to win enough Illumina Inc shareholder support to install at least one of his three nominees to the gene sequencing machine maker's board, two people familiar with the matter said on Wednesday.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Let's talk about the popular Illumina, Inc. ( NASDAQ:ILMN ). The company's shares received a lot of attention from a...
ISS backed Icahn's candidate Andrew Teno and said he could be an adequate replacement for Illumina Chairman John Thompson, but did not support any other Icahn nominee. The partial backing by ISS comes just two days after another proxy adviser, Glass Lewis, backed Teno and another Icahn nominee, and said shareholders should vote against the re-election of current CEO Francis deSouza and Chairman Thompson.
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
Glass Lewis added shareholders should vote against the re-election of the current chief Francis deSouza and chair John Thompson, saying they had enough reasons to advocate for a new chair. The recommendations come ahead of the company's annual shareholder meeting on May 25, which could bring to an end the two-month long proxy battle between Illumina and billionaire investor Carl Icahn.
Key Insights Illumina's estimated fair value is US$164 based on 2 Stage Free Cash Flow to Equity Illumina is estimated...
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).
The gene-sequencing company reported weaker results while the Federal Trade Commission has ordered it to divest its Grail acquisition.
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
EXEL vs. ILMN: Which Stock Is the Better Value Option?